---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015074"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:35:02.830970+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M

## Summary
- Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.
- Q1 total revenue $173.7M (down 27% YoY); net loss $81.8M ($0.12/share) vs $18.3M loss a year ago.
- Issued $230M 3.75% convertible notes due 2029; exchanged $144.4M of existing 4.50% notes; used $50M to repurchase common stock.
- FDA cleared IND for MDX2001 tetraspecific antibody for solid tumors; Phase 1 trial enrollment expected Q2 2024.

## SEC filing metadata
- accession: 0001437749-24-015074
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/opk20240503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015074
- JSON: https://secwatch.observer/filing/0001437749-24-015074.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015074.txt

## Key facts
- Earnings Releases
  OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.
  - Period: three months ended March 31, 2024
  - Revenue: $173.7 million
  - Net income: $81.8 million, or $0.12 per share
  - EPS: $0.12 per share
  - Result: reported results
  source text: was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.